Inhibrx Biosciences (INBX) Stock: Buy, Sell, or Hold?
INBX - Inhibrx Biosciences, Inc. Common Stock
$98.19
2.89 (3.03%)
▲
5d:
+15.17%
30d:
-11.28%
90d:
+15.52%
HOLD
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 13, 2026
21d
Get Alerted When INBX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INBX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INBX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INBX is currently trading at $98.19, which is considered fair relative to its 30-day fair value range of $91.06 to $105.52.
Technical Outlook: Technically, INBX is in a uptrend. The price is approaching resistance at $99.82. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $266.67 (+171.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INBX is in a uptrend. The price is approaching resistance at $99.82. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $266.67 (+171.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$91.06 -
$105.52
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.2%
Protect Your Profits
Holding INBX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 171.6% below Wall St target ($266.67)
- NEUTRAL: Bottoming setup forming (40/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$91.06 -
$105.52
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$12.60
(12.8%)
Support & Resistance Levels
Support Level
$83.61
Resistance Level
$99.82
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.21
Wall Street Target
$266.67
(+171.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 22, 2026 9:28 AM ET
Data refreshes hourly during market hours. Next update: 10:28 AM
Data refreshes hourly during market hours. Next update: 10:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INBX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 60 BUY |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
15 analysts |
$52 | 62 BUY |
Advanced INBX Option Strategies
Professional options setups generated by AI based on today's INBX price and gamma walls.
